Company: INVUP
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001193
Chunk: 1263

Company: Investview, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 1263
---
 As part of the settlement, we agreed
to pay the SEC a penalty of $375,000 and to cease and desist from continuing any further violations of Sections 5(a) and 5(c) of the
Securities Act of 1933, as amended.

Amendment of Credit Arrangements with DBR
Capital

On
or about February 28, 2025, the Company and DBR Capital entered into an amendment to the Securities Purchase Agreement (the “Amendment”),
approved by the disinterested members of the Company’s Board of Directors. Pursuant to the Amendment, DBR has been given until
August 31,2025 to lend to the Company a minimum of $2.0 million, and until December 31, 2026 to lend to the Company balance of up to
$5.7 million. The Amendment also substantially reduces the interest rate for the first $2 million that may be advanced by DBR Capital
from 38.5% to 18.75% per annum, and further substantially reduces the interest rate to 10% per annum (also from 38.5%) for any amounts
loaned in excess of $2 million.

Announcement of Stock Repurchase Program

On
March 6, 2025, the Board of Directors authorized a stock repurchase program that will allow the Company to repurchase up to $1,000,000
in aggregate value of shares of the Company’s common stock, par value $0.001 per share, through March 6, 2026. As of the date of
this filing, 705,890 shares have been repurchased for $16,618. These shares are being held by the Company in Treasury.

Results
of Operations

Year
Ended December 31, 2024, Compared to Year Ended December 31, 2023

Revenues

    Year Ended December 31,  
    Increase 

    2024  
    2023  
    (Decrease) 

    Membership revenue, net of refunds, incentives, credits, and chargebacks 
    $47,061,290  
    $56,036,052  
    $(8,974,762)
  
    Mining revenue 
     5,186,606  
     11,348,156  
     (6,161,550)
  
    Health and wellness product sales 
     110,671  
     -